Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already indicate read-only, idempotent, and open-world. The description adds rich behavioral context: it fetches latest SEC data for companies with correct fiscal year handling, pulls FAERS and FDA data for drugs, sorts results by primary metric, and returns citation URIs. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is well-structured, starting with common queries and then detailing behavior per type. Every sentence adds value, but it is slightly verbose (e.g., listing multiple example queries could be condensed). Overall, it earns its length without excess.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With 2 parameters and no output schema, the description thoroughly covers input usage, per-type behavior, output format (sorted results, citation URIs), and when to prefer it over other tools (replaces 8-15 sequential lookups). No gaps for an AI agent to misunderstand.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but the description adds significant meaning: it explains that 'type=company' pulls revenue, net income, cash, debt from SEC, and 'type=drug' pulls adverse event counts, FDA approvals, trial counts. For 'values', it clarifies format per type (tickers/CIKs vs. drug names) and repeats min/max constraints. This far exceeds the schema's basic descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool's purpose: side-by-side comparison of 2-5 companies or drugs. It uses explicit verbs like 'compare', 'rank', and specifies the resources ('companies', 'drugs'). It distinguishes from siblings like 'lookup' by emphasizing parallel retrieval over sequential lookups.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'ALWAYS PREFER over sequential single-pack lookups when comparing entities' and lists trigger phrases like 'compare X and Y' and 'X vs Y'. It also clarifies when to use each type ('company' for financials, 'drug' for pharma data) and implies exclusivity (not for single entity queries).

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation2/5

Several tools have heavily overlapping purposes: ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded share the same router, with the beta variant currently identical to stable. The five polymarket_* tools plus bet_research also blur boundaries, and discover_tools/suggest_questions both serve discovery. Detailed descriptions help, but an agent could easily select the wrong tool.

Naming Consistency3/5

All names use lower_snake_case and many follow a clear verb_noun pattern (resolve_entity, validate_claim, generate_llms_txt). However, there are notable deviations: entity_profile, pipeworx_feedback, polymarket_edges, recent_changes, and bet_research lead with nouns or adjectives. The style is readable and predictable in clusters, but not uniform.

Tool Count2/5

32 tools is well above the 25+ threshold for 'too many', and the server name Macvendors suggests a narrow MAC-lookup service, yet most tools belong to a much broader Pipeworx data/prediction-market platform. Several tools are near-duplicates or micro-variants (three ask_pipeworx versions, six polymarket tools). The set would be more appropriately split or heavily consolidated.

Completeness4/5

Within the actual broad research platform domain, the surface is fairly complete: discovery, routing, grounded answers, entity profiles, comparisons, recent changes, claim validation, semantic search, prediction-market analysis, subscriptions, memory, and feedback are all covered. Minor gaps exist, such as no subscription update tool and no batch MAC lookup, but agents can generally complete workflows without dead ends.